Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
An honest look at what mesenchymal stem cell (MSC) therapy is — and is not — for systemic lupus erythematosus. The published evidence comes mostly from small refractory-disease studies, not as a replacement for SLE standard of care. Care at Regeneris is physician-led, federally regulated under COFEPRIS, and delivered in Cancún, México after a free medical evaluation and individualized written plan.
Mesenchymal stem cell (MSC) therapy for lupus (SLE) is investigational — not an approved cure, and not a replacement for the hydroxychloroquine, immunosuppressant, and biologic standard of care that a rheumatologist directs. The most-studied setting is refractory disease that has not responded to conventional therapy, where small-to-medium peer-reviewed trials from China and the United States report safety signals and disease-activity reductions over 12 months and longer. Regeneris Therapy, in Cancún, México, operates under COFEPRIS — Mexico's federal health authority — and only evaluates lupus patients in coordination with their treating rheumatologist. There are no published prices: every plan is individualized in a free medical evaluation, followed by a personalized written quote.
Clinical overview
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks the patient's own tissues — joints, skin, kidneys, blood cells, brain, heart, and lungs can all be affected. The course is relapsing: flares of inflammation alternate with periods of relative quiet. Severity ranges from mild skin and joint involvement to organ-threatening disease such as lupus nephritis (kidney inflammation) or neuropsychiatric lupus. Diagnosis combines clinical features with autoantibodies (ANA, anti-dsDNA, complement levels) and is confirmed by a rheumatologist. Standard of care — hydroxychloroquine, corticosteroids, immunosuppressants such as mycophenolate or azathioprine, and approved biologics such as belimumab or anifrolumab — is directed by that specialist, and is what has the strongest published evidence behind it.
MSC therapy enters the conversation as an investigational option that is studied alongside that standard of care — most often in refractory disease, where conventional treatment has not adequately controlled the lupus. It is not a primary therapy, and it is not a substitute for the medications a rheumatologist prescribes. Any honest page on this topic must say so up front.
Where the evidence stands
Most clinical studies of MSCs in lupus come from China, with a smaller US Phase I trial and a growing body of meta-analyses. They are predominantly small, open-label, and focused on refractory disease — patients who have not adequately responded to standard immunosuppression. The signals are encouraging enough to justify continued study, but they do not establish MSC therapy as a proven cure or as a routine alternative to rheumatology-directed care. The notes below summarize the picture in conservative terms.
A pilot study of allogeneic bone-marrow MSC transplantation in patients with persistently active, refractory SLE reported clinical improvement, a marked decrease in SLEDAI disease-activity scores, and reduced 24-hour proteinuria over follow-up. The trial established initial feasibility and safety signals but is small and open-label — proof of concept, not proof of cure.
A 40-patient multicenter study of allogeneic umbilical-cord (UC) MSC transplantation in active, refractory SLE across four Chinese centers reported that the infusions were well tolerated, with no transplantation-related adverse events, and that roughly one third of patients achieved major and one quarter partial clinical response over 12 months. The authors framed UC-MSC therapy as a candidate adjunct for refractory disease — still investigational, and not a first-line treatment.
A six-year follow-up of patients who had received allogeneic UC-MSC transplantation for refractory SLE reported a generally favorable safety profile, with no serious adverse events attributed to the cells and stable laboratory parameters over the observation period. The cohort is small, but it is one of the longest published safety signals available for MSC therapy in lupus.
An open-label Phase I trial in the United States enrolled six women with treatment-refractory SLE and infused allogeneic umbilical-cord MSCs, reporting minimal adverse events and an SLE Responder Index (SRI-4) endpoint reached in five of six participants — a small but methodologically careful Western-population signal. The authors emphasize that this is early-phase data designed to support larger trials, not a basis for routine clinical use.
A 2020 meta-analysis pooling ten studies (315 SLE patients) concluded that MSC therapy was associated with lower proteinuria, higher serum albumin, higher complement C3, and a lower adverse-event rate versus controls at three months. The authors describe MSCs as 'a promising therapeutic agent' for SLE while explicitly cautioning that the included samples are small and the results warrant larger, well-controlled confirmatory trials.
Bottom line: the published evidence is real but early. It supports continued investigation of MSC therapy as an adjunct for selected refractory-SLE cases under medical supervision; it does not support marketing MSCs as a cure, as a replacement for hydroxychloroquine and immunosuppressants, or as a routine first-line therapy for all lupus patients.
Honest screening
A physician evaluation is the only place this question is properly answered. The lists below describe the kind of cases where MSC therapy is most often discussed, and the situations where it is deferred or declined — always with the patient's treating rheumatologist in the conversation.
If you are uncertain which side of the line your case falls on, that is exactly what the free medical evaluation is for. We will tell you honestly — including when the answer is 'not yet' or 'this is not the right therapy for you'.
Regulation & location
Regeneris Therapy operates in Cancún, México under COFEPRIS, the Federal Commission for the Protection against Sanitary Risks — Mexico's national health authority and the regulator most closely analogous to the U.S. FDA. Federal Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 cover the clinic and its medical communications. Mexico is also one of the relatively few countries where allogeneic mesenchymal stem cell protocols can be delivered in a private clinical setting under federal oversight — a key reason patients with autoimmune-adjacent conditions travel to Cancún for evaluation.
Our approach
There is no off-the-shelf 'lupus protocol' at Regeneris. The pathway below is how we work with every autoimmune-adjacent case in Cancún, México — physician-led, coordinated with your rheumatologist, and ending with a personalized written quote only after a free medical evaluation.
You send your diagnosis, recent labs (CBC, kidney function, complement, autoantibody panel), imaging if relevant, and your current rheumatology medications. A Regeneris physician reviews the case and tells you — honestly — whether MSC therapy is reasonable to discuss in your case, whether it should be deferred, or whether it is not a fit.
If we proceed, we coordinate directly with your treating rheumatologist. MSC therapy is positioned as an adjunct to your standard care — not a replacement — and decisions about adjusting other medications stay with your specialist.
If we proceed, the plan is documented in writing: cell source (umbilical-cord / Wharton's jelly MSCs from a COFEPRIS-certified lab), route of administration, number of sessions, expected follow-up, and a personalized written quote. Nothing is decided 'on the day'.
Treatment is delivered in our clinic in Cancún, México under physician supervision, with vitals and tolerance monitored. Patients receive a discharge summary and follow-up instructions to share with their rheumatologist.
Disease-activity scores (e.g. SLEDAI), labs (complement, anti-dsDNA, urinary protein), and symptom diaries guide a clear reassessment. If results do not justify continuing, we say so — repeat sessions are a medical decision, not a default.
Realistic expectations
Setting expectations is part of the medical work. With a chronic autoimmune disease like lupus, the only responsible posture is conservative.
FAQ
The questions patients with SLE most often send us when considering evaluation in Cancún, México.
No. Mesenchymal stem cell (MSC) therapy is not a cure for systemic lupus erythematosus. SLE is a lifelong autoimmune disease, and the only approved cures do not exist. MSC therapy is investigational for lupus, and the published evidence — small clinical trials, mostly in refractory disease — describes disease-activity reductions and immunomodulation in selected patients, not elimination of the disease. Any clinic that promises a cure is overstating what the science supports.
That is not a decision a regenerative clinic should make — it belongs to your treating rheumatologist. At Regeneris in Cancún, México we position MSC therapy as an adjunct to your standard care, not a replacement. Any medication changes are coordinated by your specialist, based on your disease activity, labs, and clinical course over months of follow-up. Patients who arrive expecting to stop their lupus medications because of a stem cell infusion are politely redirected to that conversation with their rheumatologist.
When MSC therapy is appropriate for a lupus case, Regeneris uses allogeneic umbilical-cord (Wharton's jelly) mesenchymal stem cells processed in a COFEPRIS-certified laboratory chain in México. This is the cell source most represented in the lupus literature — including the Chinese multicenter UC-MSC study (Wang 2014), the six-year safety follow-up (Wang 2017), and the US Phase I trial (Wang 2022). Cell source, dose, route, and number of sessions are individualized for your case and stated in your written plan.
Yes. Regeneris Therapy operates in Cancún, México under COFEPRIS — the Federal Commission for the Protection against Sanitary Risks, México's national health authority and the regulator most closely analogous to the U.S. FDA. The clinic holds federal Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053. MSC products are processed in a COFEPRIS-certified laboratory, and every protocol is physician-led. México is one of the countries where allogeneic MSC protocols can be delivered in a private clinical setting under federal oversight, which is one reason patients evaluate care here.
It starts with a free medical evaluation: you send your SLE diagnosis confirmation, recent labs (CBC, kidney function, complement, autoantibody panel), imaging if relevant, and your current rheumatology medications. A Regeneris physician reviews the case and replies honestly — including when the answer is 'not yet' or 'not a fit'. If we proceed, we coordinate directly with your rheumatologist, document an individualized plan and personalized written quote, deliver treatment in our clinic in Cancún, and follow up with disease-activity scores and labs at defined intervals.
Regeneris does not publish prices online. Every plan is individualized — cell source, dose, number of sessions, and follow-up depend on your specific case, severity, and goals — so the only honest figure is the one in your personalized written quote, which follows a free medical evaluation. Lupus evaluation also requires us to confirm with your rheumatologist that adjunctive therapy makes sense for you, and that conversation happens before any quote is issued. If you are price-shopping a webpage, this page deliberately gives you none; if you want a real number for your case, we will be straightforward in writing.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris: cell sources, mechanism, protocols, and how to start.
ContinueHow regenerative therapy is regulated in México and what 'COFEPRIS-certified' actually means for cell sourcing and clinical delivery.
ContinueTravel, regulation, and logistics for US and Canadian patients evaluating regenerative care in Cancún, México.
ContinueA 2026 comparison of regulation, available cell types, and cross-border logistics for regenerative care.
ContinueSend your case for a free medical evaluation. We respond personally — never with a brochure.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for systemic lupus erythematosus is investigational — most evidence comes from small refractory-disease studies, outcomes vary, and MSC therapy is not a substitute for rheumatologist-directed standard of care (hydroxychloroquine, immunosuppressants, biologics). The decision to evaluate or pursue MSC therapy requires a free medical evaluation with a licensed physician at Regeneris Therapy in Cancún, México, in coordination with your treating rheumatologist; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053. No prices are published on this page.
Book a free 15-min call with our team.
Send your SLE diagnosis confirmation, recent labs, and the lupus medications you are on. A Regeneris physician will review your case in Cancún, México and tell you honestly whether MSC therapy is reasonable to discuss — with a personalized written quote after your free medical evaluation. No prices on this page; real numbers in writing once we know your case.